ArticleThe Lancet regional health. Europe2024
Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis.
Abstract read
In one paragraph
Article in The Lancet regional health. Europe, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of Hepatitis C Among Migrants: A Systematic Review and Meta-Analysis.Journal of viral hepatitis · 2025Pooled it
- Universal HCV Screening in Hospitalised Patients in France: It Could Be a Good Option! The DEVICHO Study.Journal of viral hepatitis · 2025Trial
- EuroHePP: The European Toolkit to Strengthen National Responses for the Elimination of Viral Hepatitis in Prisons.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Five Years of HCV Dried Blood Spot Testing in At-Risk Populations and the Impact of Reduced Sensitivity on Missed Diagnoses.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Viral hepatitis detection through emergency hospital departments in a Spanish region with high immigration: implications for elimination strategies.Infectious diseases of poverty · 2026Observational
- Mortality Attributable to Hepatitis B and C in Italy, Romania, and Spain, 2022 Estimates.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Trends in mortality and years of life lost among patients with cirrhosis and hepatocellular carcinoma in France, 2011-2023: a nationwide retrospective population-based study.The Lancet regional health. Europe · 2026Article
- From targets to real world impact: a review of models of care for chronic HBV and HCV in Europe.The Lancet regional health. Europe · 2026Review
- Prevalence of Active HCV Infection in Spain in 2022 Using Multiparameter Evidence Synthesis.Journal of viral hepatitis · 2026Article
- Use of the Workbook Method to estimate the prevalence of chronic hepatitis B infections in the European Union and European Economic Area, 2022.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- A Retrospective Description of Pediatric Hepatitis C in a Romanian Cohort: Liver Fibrosis at Diagnosis.Diagnostics (Basel, Switzerland) · 2026Article
- Prevalence of Viral Hepatitis Antibodies Among Alcoholics in Croatia: A Single Center's Results.Antibodies (Basel, Switzerland) · 2026Article
- Enhanced detection of HBV and HCV using Cas13a-FLAP and FGoAI platforms.Chemical science · 2026Article
- Marked Reduction in HIV/HCV Coinfections in Iceland Following the TraP HepC Nationwide Hepatitis C Elimination Program.Open forum infectious diseases · 2026Article
- Active and resolved HCV infections among people with new HIV-1 diagnoses in Germany, 2009-2019.BMC infectious diseases · 2025Article
- Article
- Review
- Standardising monitoring data on drug-related infectious diseases among people who inject drugs in Europe - an update of the European Union Drugs Agency technical protocol, 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Addressing viral hepatitis C reinfections in a low-threshold programme for people who inject drugs in Slovenia.Harm reduction journal · 2025Article
- Estimated number of people infected with hepatitis B and C virus in Germany in 2013: a baseline prevalence estimate using the workbook method.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
65 authors.
Christos ThomadakisMedical School, University of Cyprus, Nicosia, Cyprus.
Ilias GountasMedical School, University of Cyprus, Nicosia, Cyprus.
Erika DuffellEuropean Centre for Disease Prevention and Control, Stockholm, Sweden.
Konstantinos GountasMedical School, University of Cyprus, Nicosia, Cyprus.
Benjamin BluemelEuropean Centre for Disease Prevention and Control, Stockholm, Sweden.
Thomas SeylerEuropean Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal.
Filippo Maria PericoliEuropean Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal.
Irene Kászoni-RückerlVII/A/11 Communicable Diseases and Disease Control, Federal Ministry of Social Affairs, Health, Care and Consumer Protection, Vienna, Austria.
Ziad El-KhatibInstitute for Surveillance & Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety (AGES), Vienna, Austria.
Martin BuschAddiction Competence Center, Austrian National Public Health Institute, Vienna, Austria.
Irene SchmuttererAddiction Competence Center, Austrian National Public Health Institute, Vienna, Austria.
Thomas VanwolleghemViral Hepatitis Research Group, Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium.
Sofieke KlamerDepartment of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Els PlettinckxDepartment of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Laure MortgatDepartment of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Dominique Van BeckhovenDepartment of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Tonka VarlevaScientific Research Institute, Medical University, Pleven, Bulgaria.
Mirjana Lana Kosanovic LicinaCommunicable Disease Epidemiology Department, Andrija Stampar Teaching Institute of Public Health, Zagreb, Croatia.
Tatjana Nemeth BlazicDepartment for HIV, Sexual and Blood Transmitted Diseases, Reference Center of the Epidemiology of the Ministry of Health, Croatian Institute of Public Health, Zagreb, Croatia.
Diana NonkovićTeaching Institute of Public Health Split and Dalmatia County, Split, Croatia.
Fanitsa TheophanousMinistry of Health, Nicosia, Cyprus.
Vratislav NemecekNational Reference Laboratory for Viral Hepatitis, National Institute of Public Health, Prague, Czech Republic.
Marek MalyDepartment of Biostatistics, National Institute of Public Health, Prague, Czech Republic.
Peer Brehm ChristensenDepartment of Infectious Diseases, Odense University Hospital, Odense, Denmark.
Susan CowanDepartment of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.
Kristi RüütelNational Institute of Health Development, Tallinn, Estonia.
Henrikki Brummer-KorvenkontioFinnish Institute for Health and Welfare, Helsinki, Finland.
Cécile BrouardSanté Publique France, The National Public Health Agency, Saint-Maurice, France.
Gyde SteffenDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Amrei KringsDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Sandra DudarevaDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Ruth ZimmermannDepartment of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Georgia NikolopoulouNational Public Health Organization, Marousi, Greece.
Zsuzsanna MolnárNational Center for Public Health and Pharmacy, Budapest, Hungary.
Emese KozmaNational Center for Public Health and Pharmacy, Budapest, Hungary.
Magnús GottfredssonFaculty of Medicine, School of Health Sciences, University of Iceland, Reykjavík, Iceland.
Niamh MurphyHSE Health Protection Surveillance Centre, Dublin, Ireland.
Loreta A KondiliNational Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
Maria Elena TostiNational Center for Global Health, Istituto Superiore di Sanità, Rome, Italy.
Anna Rita CiccaglioneViral Hepatitis, Oncovirus and Retrovirus Disease Unit, Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Barbara SuligoiNational AIDS Unit, Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Raina NikiforovaThe Centre for Disease Prevention and Control, Riga, Latvia.
Renate PutninaThe Centre for Disease Prevention and Control, Riga, Latvia.
Ligita JancorieneClinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty, Vilnius University, Vilnius, Lithuania.
Carole Seguin-DevauxDepartment of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.
Tanya MelilloInfectious Disease Prevention and Control Unit, Health Promotion and Disease Prevention Directorate, Department of Health Regulation, Ministry for Health, Gwardamangia, Malta.
Anders BoydDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Marc van der Valkstichting hiv monitoring, Amsterdam, the Netherlands.
Eline Op de CoulCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Robert WhittakerSection for Respiratory, Blood-borne and Sexually Transmitted Infections, Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway.
Hilde KløvstadSection for Respiratory, Blood-borne and Sexually Transmitted Infections, Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway.
Małgorzata StępieńDepartment of Infectious Disease Epidemiology and Surveillance, National Institute of Public Health NIH - National Research Institute, Warsaw, Poland.
Magdalena RosińskaDepartment of Infectious Disease Epidemiology and Surveillance, National Institute of Public Health NIH - National Research Institute, Warsaw, Poland.
Cristina ValenteDepartment of Infectious Diseases, Hospitais da Universidade de Coimbra, Directorate General of Health, Coimbra, Portugal.
Rui Tato MarinhoCentro Hospitalar Universitário Lisboa Norte, Medical School of Lisbon, Directorate General of Health, Ministry of Health, Lisbon, Portugal.
Odette PopoviciNational Centre for Surveillance and Control of Communicable Diseases, National Institute of Public Health Romania, Bucharest, Romania.
Mária AvdičováDepartment of Epidemiology, Regional Authority of Public Health in Banská Bystrica, Banská Bystrica, Slovakia.
Jana KerlikDepartment of Epidemiology, Regional Authority of Public Health in Banská Bystrica, Banská Bystrica, Slovakia.
Irena KlavsNational Institute of Public Health, Ljubljana, Slovenia.
Mojca MaticicClinic for Infectious Diseases, University Medical Centre Ljubljana and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Asuncion DiazNational Centre of Epidemiology, Carlos III Health Institute, CIBER in Infectious Diseases (CIBERINFEC), Madrid, Spain.
Julia Del AmoDivision for HIV, STI, Viral Hepatitis and Tuberculosis Control, Ministry of Health, Madrid, Spain.
Josefine Lundberg EderthPublic Health Agency of Sweden, Solna, Sweden.
Maria AxelssonPublic Health Agency of Sweden, Solna, Sweden.
Georgios NikolopoulosMedical School, University of Cyprus, Nicosia, Cyprus.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019. Methods: Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = π Findings: The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50% [95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs. Interpretation: Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID. Funding: ECDC.
Indexed as
Chronic hepatitisEliminationEuropeHCVHepatitis CPrevalence
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.